Company intelligence / Profile preview

Zentalis Pharmaceuticals

New York, New York, United Stateszentalis.com ↗

Ownership: Public · ZNTL
Development stage: Phase 2

Overview

Lead candidate azenosertib (WEE1 inhibitor) has shown anti-tumor activity as a single agent across multiple tumor types and in combination with several chemotherapy backbones. The company is exploring enrichment strategies targeting tumors of high genomic instability.

Therapeutic areas: Oncology
Modalities: Small moleculesProtein degraders
Industry: Biotech

Drug pipeline

4 assets

azenosertib

3 more assets in the full pipeline.

Request access →

Partnerships

Pfizer IncMayo ClinicSciClone Pharmaceuticals Inc

Financials

Market cap: $270.5M
Total revenue: $0
Enterprise value: $133.6M

Beyond the preview

Go deeper on Zentalis Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zentalis Pharmaceuticals.

Explore the full profile